Business
PepGen Announces Appointment of Two New Directors to its Board
BOSTON, March 31, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive experience in the life sciences to the Company.
About this update from Pepgen Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/046e5e25eb36d2f174fc3597bfb47722"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7lePCpGeflEV8YMmeq9Ffw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/046e5e25eb36d2f174fc3597bfb47722","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/SEN7w2LfkVPhr4x.uZKa2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/046e5e25eb36d2f174fc3597bfb47722","width":1024,"height":512}},"lazy":false},{"type":"text","content":"BOSTON, March 31, 2025--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive experience in the life sciences to the Company.","length":493,"tagName":"p"},{"type":"text","content":""We are thrilled to welcome Lisa and Mitch to our Board of Directors," said James McArthur, PhD, President and CEO of PepGen. "Lisa’s proven ability to scale manufacturing for mid- to late-stage clinical trials and guide clinical-stage companies through global regulatory agencies, combined with Mitch’s extensive experience in driving scientific innovation and translating breakthrough research into life-changing therapies, will broaden and strengthen our Board of Directors at this crucial time for PepGen. Their guidance will be invaluable as we advance our mid-stage clinical trials and continue to unlock the full potential of our cutting-edge Enhanced Delivery Oligonucleotide platform, with the ultimate goal of bringing transformative therapeutics to patients with severe neuromuscular conditions."","length":827,"tagName":"p"},{"type":"text","content":"Ms. Wyman was recently appointed Chief Technical and Quality Officer at Scholar Rock. Previously, she served as Chief Technical Operations Officer and Chief Digital Officer at Generate:Biomedici...